Imbio PHA (4.0.0) vs Eko Low Ejection Fraction Tool (ELEFT)
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your clinical workflow involves analyzing CT pulmonary angiogram (CTPA) scans and you require automated, precise measurements of cardiac structures. This tool is ideal for radiologists and cardiologists needing to assess right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension, integrating seamlessly with existing DICOM workflows for detailed post-imaging analysis.
View Imbio PHA (4.0.0) →Choose Eko Low Ejection Fraction Tool (ELEFT) if…
Choose Eko Low Ejection Fraction Tool (ELEFT) if you are a clinician performing routine physical exams and need a rapid, non-invasive screening tool for early detection of low ejection fraction. This AI algorithm, integrated with Eko digital stethoscopes, is best suited for primary care, family medicine, or cardiology settings where quick identification of potential heart failure risk during a patient encounter is paramount.
View Eko Low Ejection Fraction Tool (ELEFT) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Low Ejection Fraction Tool (ELEFT)Eko ELEFT offers superior usability for a broader range of clinicians due to its rapid, non-invasive screening capability during routine physical exams, providing results in approximately 15 seconds. While Imbio PHA integrates well into existing radiology workflows, ELEFT's point-of-care application with a familiar device like a stethoscope makes it highly accessible for immediate clinical decision-making.
Clinical Value
TieBoth tools are FDA-cleared and provide significant clinical value in their respective domains. Imbio PHA offers detailed quantitative diagnostic information from CTPA scans for pulmonary embolism and hypertension, while Eko ELEFT enables crucial early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams. Their impact is high, but in different stages and contexts of patient care.
Pricing & Value
TieNeither product provides transparent pricing, with both requiring direct contact for specific quotes. Tool B is explicitly stated to be part of an 'enterprise solution' platform, which might imply a bundled cost, but without concrete pricing details for either, a direct comparison of their financial value is not feasible.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA demonstrates greater enterprise readiness by offering flexible deployment options including cloud, on-premise, or via partners, accommodating diverse IT infrastructures and data governance needs. Although Eko ELEFT is part of an enterprise platform and is HIPAA compliant, its cloud-based deployment integrated with specific hardware may be less adaptable for some large organizations compared to Imbio's broader options.
Innovation
Eko Low Ejection Fraction Tool (ELEFT)Eko ELEFT presents a more disruptive innovation by integrating AI-powered diagnostics with a traditional physical exam tool, the digital stethoscope, for real-time, non-invasive screening at the point of care. While Imbio PHA innovates by automating complex measurements from existing imaging, ELEFT's approach expands diagnostic capabilities into routine patient interactions in a novel way.
Support & Docs
Imbio PHA (4.0.0)Imbio provides clear and direct support channels, including phone and email support, and an online case submission form, explicitly stating that user manuals and product documentation are available upon request. While Eko Health offers a help center and various contact methods, some customer feedback suggests potential inconsistencies in their support responsiveness.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Primary Clinical Focus | Assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | Aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure. |
| Input Modality/Data | CT pulmonary angiogram (CTPA) scans. | ECG and heart sound recordings from Eko digital stethoscopes. |
| Key Measurements/Detection | Automated measurement of right and left ventricle diameters, automated measurement of main pulmonary artery and aorta diameters, calculates RV/LV and PA/Ao ratios. | AI-powered low ejection fraction detection. |
| Target Medical Specialties | Cardiology, Pulmonology, Radiology. | Cardiology, Family Medicine, Internal Medicine. |
| Result Output | Annotated DICOM images, summary reports in PDF format. | Not specified |
| Processing Time | Rapid, fully-automated assessment (typically in minutes). | Approximately 15 seconds. |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Eko Low Ejection Fraction Tool (ELEFT).
Frequently Asked Questions
More Comparisons
More matchups featuring Imbio PHA (4.0.0) or Eko Low Ejection Fraction Tool (ELEFT)
Backers
Who funded each tool's parent company.